Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is August 13, 2025, covering a share repurchase executed on August 12, 2025. The transaction was conducted through Merrill Lynch International as part of an existing non-discretionary buyback agreement initiated on June 4, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial results. Key metrics for this transaction include:
- Shares Purchased: 495,245 ordinary shares.
- Price Range: Lowest price paid was 1,395.50 GBp; highest price paid was 1,405.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,401.27 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Shares: Following this purchase, GSK holds 241,032,621 ordinary shares in treasury.
- Shares in Issue: 4,074,358,625 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 5.92% of total voting rights.
The filing does not provide data on revenue, profit, cash flow, margins, or debt levels.
Material Changes
Since the commencement of the buyback program on June 4, 2025, GSK has purchased a total of 22,898,238 ordinary shares. The August 12 transaction represents a continuation of this program. There are no other material changes to the company's financial position or operations disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no new guidance or management commentary regarding future financial performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties. Investors are directed to the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and the Q2 Results for 2025 for details on potential risks.
Important Facts for Investors to Verify
- Confirm the total remaining authorization under the buyback program initiated on June 4, 2025.
- Verify the impact of the 5.92% treasury share holding on earnings per share (EPS) calculations.
- Review the Q2 2025 results and the 2024 Form 20-F for comprehensive financial performance and risk factors not covered in this transaction report.
- Monitor future 6-K filings for updates on the buyback program's progress and completion.